Cargando…

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Chronic hepatitis C can be treated very effectively with direct-acting antivirals (DAA) with only minor side effects compared to an interferon-containing treatment regimen. The significance of metabolic comorbidities after HCV cure is not well defined. This study aims to investigate short- and long-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlevogt, Bernhard, Boeker, Klaus H. W., Mauss, Stefan, Klinker, Hartwig, Heyne, Renate, Link, Ralph, Simon, Karl-Georg, Sarrazin, Christoph, Serfert, Yvonne, Manns, Michael P., Wedemeyer, Heiner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533115/ https://www.ncbi.nlm.nih.gov/pubmed/34680612 http://dx.doi.org/10.3390/biomedicines9101495

Ejemplares similares

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R)
por: Christensen, Stefan, et al.
Publicado: (2019)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry
por: Tacke, Frank, et al.
Publicado: (2022)

Real‐world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)
por: Krüger, Kathrin, et al.
Publicado: (2022)

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)
por: Cornberg, Markus, et al.
Publicado: (2022)

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry
por: Rau, Monika, et al.
Publicado: (2022)

Expert opinion on the treatment of patients with chronic hepatitis C
por: Zeuzem, S, et al.
Publicado: (2009)

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry
por: Hinrichsen, Holger, et al.
Publicado: (2020)

The New Era of Interferon-Free Treatment of Chronic Hepatitis C
por: Solbach, Philipp, et al.
Publicado: (2015)

Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA
por: Heidrich, Benjamin, et al.
Publicado: (2014)

Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C
por: Owusu Sekyere, Solomon, et al.
Publicado: (2015)

The DHC1b (DHC2) Isoform of Cytoplasmic Dynein Is Required for Flagellar Assembly
por: Pazour, Gregory J., et al.
Publicado: (1999)

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C
por: Markova, Antoaneta A., et al.
Publicado: (2014)

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
por: Hofmann, Wolf Peter, et al.
Publicado: (2015)

Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients
por: Pischke, Sven, et al.
Publicado: (2012)

Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection
por: Solbach, Philipp, et al.
Publicado: (2015)

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta
por: Sandmann, Lisa, et al.
Publicado: (2021)

Additional challenges in reaching hepatitis C elimination goals in Germany due to the COVID-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021
por: Meyer, Emily D., et al.
Publicado: (2023)

Hepatitis C new drugs
por: Wedemeyer, H
Publicado: (2010)

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study
por: Stahmeyer, Jona T., et al.
Publicado: (2016)

Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity
por: Strunz, Benedikt, et al.
Publicado: (2018)

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
por: Witthöft, Th, et al.
Publicado: (2007)

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting
por: Wiegand, Steffen B., et al.
Publicado: (2015)

Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study
por: Buggisch, Peter, et al.
Publicado: (2021)

Psoriasis and Hepatitis C: Improvement with Interferon
por: Habte-Gabr, Eyassu, et al.
Publicado: (2011)

Irreversible impact of chronic hepatitis C virus infection on human natural killer cell diversity
por: Strunz, Benedikt, et al.
Publicado: (2018)

Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing
por: Stahl, Yannick, et al.
Publicado: (2023)

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal
por: Sarrazin, Christoph, et al.
Publicado: (2021)

Hepatitis C and Metabolic Disorders: Genetics, Mechanism, and Therapies (Clinical and Experimental)
por: Alvares-da-Silva, Mario Reis, et al.
Publicado: (2012)

1981. Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results from the German Hepatitis C-Registry
por: Reimer, Jens, et al.
Publicado: (2018)

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response
por: Cloherty, Gavin, et al.
Publicado: (2016)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
por: Maasoumy, Benjamin, et al.
Publicado: (2013)

Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C
por: Susser, Simone, et al.
Publicado: (2014)

Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection
por: Jaroszewicz, Jerzy, et al.
Publicado: (2012)

Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C
por: Khera, Tanvi, et al.
Publicado: (2021)

Impfstoffe gegen Hepatitis E: Wo stehen wir?
por: Behrendt, Patrick, et al.
Publicado: (2022)

Neuroprotective Effects of Early Hypothermia Induced by Phenothiazines and DHC in Ischemic Stroke
por: Han, Yun, et al.
Publicado: (2021)

Breakthroughs in hepatitis C research: from discovery to cure
por: Manns, Michael P., et al.
Publicado: (2022)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

354 Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding to Interferon/Ribavirine Therapy
por: Pijak, Michal R., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fr82he8qoldj2mmie9v1l2rog1